CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech that has worked hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix. In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications. CytoDyn's […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn's inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.


While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the past several shares of mine. My first CytoDyn article, "CytoDyn: What To Do When It is Too Good to be able to Be True?", set away the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview which I came away with a bad impression of the business.

Irony of irony, the bad opinion of mine of the business enterprise has grown steadily, although the disappointment hasn't been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today's transaction of $3.5 zillion transfers ownership of this technology and connected intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance.... milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and also the first new drug program approval ($5 million), and also royalty payments of 5 % of net sales after commercialization.

Since that time, CytoDyn's helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it has this single treatments in addition to a "broad pipeline of indications" because it puts it. I call some pipelines, "pipedots." In CytoDyn's case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple presentations and multiple publications.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself with the really start of the interest of mine in this business. Judging by way of the multiples of thousands of several responses on listings accessible via Seeking Alpha's CytoDyn Summary webpage, I'm far from alone in this question.

CytoDyn is a classic battleground, or some might say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *